Table 1.
Baseline Demographic and Clinical Characteristicsa
| Characteristic | CCRT (n=40) | RT Alone (n=25) | Total (N=65) | P Value |
|---|---|---|---|---|
| Age | 0.002b | |||
| Mean (SD) | 61.4 (11.2) | 71.5 (12.4) | 65.3 (12.6) | |
| Range | (32.0–83.0) | (43.0–89.0) | (32.0–89.0) | |
| Sex, No. (%) | 0.20c | |||
| Female | 6 (15.0) | 7 (28.0) | 13 (20.0) | |
| Male | 34 (85.0) | 18 (72.0) | 52 (80.0) | |
| Race (self-identified), No. (%) | >0.99d | |||
| American Indian/Alaska Native | 1 (2.5) | 0 (0.0) | 1 (1.5) | |
| Asian | 1 (2.5) | 0 (0.0) | 1 (1.5) | |
| Black | 1 (2.5) | 1 (4.0) | 2 (3.1) | |
| Pacific Islander | 1 (2.5) | 0 (0.0) | 1 (1.5) | |
| White | 36 (90.0) | 24 (96.0) | 60 (92.3) | |
| Radiotherapy, No. (%) | 0.03c | |||
| Adjuvant | 21 (52.5) | 20 (80.0) | 41 (63.1) | |
| Definitive | 19 (47.5) | 5 (20.0) | 24 (36.9) | |
| Dose of radiation | 0.05b | |||
| Median | 60.0 | 60.0 | 60.0 | |
| Range | (50.0–70.0) | (50.0–70.0) | (50.0–70.0) | |
| Staging, No. (%) | NA | |||
| Stage I | 0 (0.0) | 6 (24.0) | 6 (9.2) | |
| Stage II | 4 (10.0) | 5 (20.0) | 9 (13.8) | |
| Stage III | 7 (17.5) | 3 (12.0) | 10 (15.4) | |
| Stage IV | 29 (72.5) | 10 (40.0) | 39 (60.0) | |
| Recurrent | 5 (12.5) | 7 (28.0) | 12 (18.5) | |
| Primary Site, No. (%) | NA | |||
| Oral cavity/oropharynx | 23 (57.5) | 6 (24.0) | 29 (44.6) | |
| Larynx | 4 (10.0) | 4 (16.0) | 8 (12.3) | |
| Skin | 2 (5.0) | 6 (24.0) | 8 (12.3) | |
| Nasopharynx | 5 (12.5) | 0 (0.0) | 5 (7.7) | |
| Nasal cavity/paranasal sinus | 0 (0.0) | 4 (16.0) | 4 (6.2) | |
| Salivary | 1 (2.5) | 3 (12.0) | 4 (6.2) | |
| Other | 4 (10.0) | 3 (12.0) | 7 (10.8) | |
| Histologic diagnosis, No. (%) | NA | |||
| Squamous cell carcinoma | 36 (90.0) | 15 (60.0) | 51 (78.5) | |
| Spindle cell carcinoma | 0 (0.0) | 2 (8.0) | 2 (3.1) | |
| Papillary thyroid | 0 (0.0) | 2 (8.0) | 2 (3.1) | |
| Melanoma | 0 (0.0) | 2 (8.0) | 2 (3.1) | |
| Merkel cell | 2 (5.0) | 0 (0.0) | 2 (3.1) | |
| Adenocarcinoma | 1 (2.5) | 1 (4.0) | 2 (3.1) | |
| Other | 1 (2.5) | 3 (12.0) | 4 (6.2) | |
| Concurrent chemotherapy, No. (%) | NA | |||
| Cisplatin | 22 (55.0) | 0 (0.0) | 22 (33.8) | |
| Cetuximab | 7 (17.5) | 0 (0.0) | 7 (10.8) | |
| Carboplatin | 5 (12.5) | 0 (0.0) | 5 (7.7) | |
| Cisplatin after induction | 3 (7.5) | 0 (0.0) | 3 (4.6) | |
| Cetuximab after induction | 1 (2.5) | 0 (0.0) | 1 (1.5) | |
| Cetuximab, carboplatin, paclitaxel | 1 (2.5) | 0 (0.0) | 1 (1.5) | |
| Induction only | 1 (2.5) | 0 (0.0) | 1 (1.5) | |
| None | 0 (0.0) | 25 (100.0) | 25 (38.5) |
Abbreviations: CCRT, concurrent chemoradiotherapy; RT, radiotherapy.
a
Percentages do not add to 100 because of rounding.
b
Wilcoxon rank sum test.
c
χ2 text.
d
Fisher exact test.